OBJECTIVEThe aim of the present study was to investigate nephrotoxicity development ratios and clinical resultsof nephrotoxicity in patients diagnosed with lung cancer who received cisplatin in chemotherapyprotocol.METHODSA total of 170 lung cancer patients were enrolled in the present prospective study. Renal functions wererecorded for each patient before and after chemotherapy. Nephrotoxicity was defined as doubling in plasmacreatinine concentration. Modification in treatment due to nephrotoxicity (reduction in cisplatin dosage,cisplatin interruption, or discontinuation of chemotherapy) was recorded during chemotherapy courses.RESULTSDecreasement of creatinine clearance levels was observed following each course of chemotherapy, butwas especially noteworthy following the 1st and 5th courses (p=0.002; p=0.007, respectively). Nephrotoxicitywas observed in 19 of the 170 patients (11%), in 10 of whom (53%) cisplatin dosage was reduced,and in 8 of whom (42%), cisplatin treatment was interrupted. Chemotherapy was discontinued in 1patient (5%).CONCLUSIONParticularly following the fourth course, chemotherapy must be carefully administered due to risk of nephrotoxicity.